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Abstract: With the expiration of patent protection for several biologics looming, the production of highly similar therapeutic agents has begun to emerge on the pharmaceutical market.
These alternative drugs are referred to as biosimilars. Many anticipate that the introduction of
these agents will result in a reduction in health care costs, which may create a more affordable
biopharmaceutical market and also improve patient access. In contrast to generics, which are
exact copies of their original products, biosimilars are not identical to their reference products.
Due to concern about the safety and efficacy of biosimilars, separate regulatory approval
pathways have been developed and implemented by several countries, including the US and
Europe. Europe has led the way in acceptance of biosimilars into mainstream clinical practice.
Biosimilars are not generic products and require extensive clinical and nonclinical bioequivalence studies before receiving marketing approval. Not only is there a lengthy developmental
process, but also they will likely be required to have postmarketing surveillance and ongoing
safety monitoring to keep track of issues that may arise, such as immunogenicity. Although US
Food and Drug Administration approved the first biosimilar product in March 2015, physicians
remain unfamiliar about their indications.
Keywords: biologics, biopharmaceuticals, biomimics, biocopies, interchangeability,
immunogenicity

Introduction

Correspondence: Alison Ehrlich
Department of Dermatology, The
George Washington University Medical
Faculty Associates, 2150 Pennsylvania
Avenue NW, Suite 2B-430, Washington,
DC 20037, USA
Tel +1 202 741 2625
Email aehrlich@mfa.gwu.edu

The emergence of biologics has been a major advancement in the management of various
chronic diseases that were previously unresponsive to conventional therapies. Biologics
are large proteins derived from living organisms or cells and manufactured through a
highly complex biotechnological process.1 Examples of biological agents are hormones,
interferons, monoclonal antibodies, interleukins, and vaccines. Although these drugs
are very efficacious, cost is a major factor for patients. Moreover, the growing concern
about the cost of drugs, including biologics, has now become a major political issue in
many countries including the US. Thus, biosimilars may represent a more economical
alternative to the costly biological agents already on the market (Table 1).
The biologic market is a highly profitable one, with a reported $157 billion in global
sales in 2011 with projections to exceed $200 billion by 2016.2,3 Global pharmaceutical
sales of biologics are likely to constitute ~49% of the market by 2018.4 The average
daily cost of a biologic drug in the US is $45 when compared to nonbiologic drugs
that sell at $2.5 The multifaceted development, manufacturing, and regulation associated with creating a biologic are the factors that cause the drug to have a significant
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Table 1 Comparison of biologics and biosimilars
Manufacturing
Immunogenicity
Regulation
Indications

Potential for
patent licensing
Potential for
exclusivity period
Potential for
interchangeability

Biologics

Biosimilars

Heterogeneous product
Potential risk
BLA
Only for those approved
by the US Food and
Drug Administration
Yes

Heterogeneous product
Potential risk
aBLA
All indications of the
original biologics

Yes, 12 years

No

No

Yes

No

Note: Data from Blackstone and Fuhr5 and Camacho et al.9
Abbreviations: BLA, biologics license application; aBLA, abbreviated biologics
license application.

cost. According to Silver, the development of an innovative
biologic drug was estimated to cost at least $1.9 billion in
2012. Similarly, significant investment is required to develop
a biosimilar, as its innovation takes an average of 7–8 years.5
However, the cost of this innovation is estimated to range
from $100 to $250 million, as compared to the ~$2 billion
required for innovator biologic drugs.5,6 In sharp contrast to
biologics and biosimilar development costs, generic drug
production costs are estimated to be from $1 to $4 million.5
The production costs for generic drugs are reported to be
low once the drug has obtained approval from US Food and
Drug Administration (US FDA); in contrast, the production
costs of biosimilars may be high, largely due to the unique
purification and processing of the drug to protect against
immunogenicity and ensure development of a highly similar
product.5,7
The European Union (EU) has led the way in the use of
biosimilars, with the first approval being epoetin biosimilars
(Abseamed, Binocrit, epoetin alfa hexal, Retacrit,
and Silapo) in 2007 in Europe.8 As of 2014, biosimilars in
Europe were priced up to 35% less than the original biologic
price.9 The anticipation of these new alternative drugs in the
EU resulted in the development of guidelines to assess the
similarity and safety between biosimilars and their reference products. The European Medicines Agency (EMA)
established a regulatory pathway in 2005.9 Because of their
experience with biosimilars, the EMA guidelines are widely
accepted as a model for other countries looking to incorporate
biosimilars into their pharmaceutical market place, as well
as learn from their successes and failures.9
A potential barrier for pharmaceutical companies in
biosimilar production is the complexity of their approval
requirements. The fact that significant time and monetary
investment are required, coupled with the uncertainty of
5
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timely approval and the cost of postapproval marketing,
encourages pharmaceutical companies to selectively develop
biosimilars for licensed biologics that garner higher sales.
In this way, extensive investments can be justified by substantial profit.5
In this review, we provide an overview of biosimilars and
address important factors for practicing clinicians, including
the 1) differences in manufacturing processes, 2) description
of the regulatory pathways, and 3) discussion of interchangeability and substitution, immunogenicity, and extrapolation
of indications.

Terminology/definitions
The use of unique and new terminology when discussing
biopharmaceuticals (biologics, biosimilars, and generics)
fuels the misconceptions and uncertainty of clinicians in
regard to biosimilar utilization. Here, we define the common terms used when referring to the biopharmaceutical
developmental process.
A biologic is a protein created by recombinant DNA
expression in live cells that has a therapeutic effect on human
diseases.10,11 Examples of biologics include fusion proteins,
monoclonal antibodies, hormones, and cytokines.11,12 Indications for use vary widely, including management of psoriasis,
chronic urticaria, atopic dermatitis, rheumatoid arthritis, and
inflammatory bowel disease.
A biosimilar, also referred to as a “follow-on biologic”,
is a biological product that is marketed as an alternative
to the original biologic, which shares highly similar, but
not identical, safety, and efficacy profiles.8 Biosimilars are
highly complex three-dimensional protein structures that are
derived from living cell lines and have therapeutic effects.13
They are biological medicine’s analogs to generics for the
synthetically derived pharmaceutical market; however, they
are not considered to be part of the “generics” category of
pharmaceuticals.
Biosimilars are not the same as “biomimics” and “biocopies”, which are intended copies of monoclonal antibodies
and fusion proteins, respectively, that have not demonstrated
bioequivalence to their reference biologics. These biologic
agents are available in a few countries.14 Bolivia, India,
People’s Republic of China, and some Latin American
countries have approved and licensed several of these drugs,
such as Yisaipu (biocopy of etanercept) and Reditux
(biocopy of rituximab).14–16 Biomimics preceded biosimilars
in marketing, including the biomimic Yiasaipu, which has
been on the market in the People’s Republic of China for
over a decade.16 Unfortunately, some biomimics have been

Clinical, Cosmetic and Investigational Dermatology 2016:9

Dovepress

responsible for more adverse events compared to their reference biologics. For example, Kikuzubam®, a biocopy of
rituximab manufactured in Mexico City, was taken off the
market in March 2014 due to several reports of anaphylactic
reactions occurring when patients switched from the original
biologic to the biomimic.14
Generic drugs have small molecular chemical structure
and are exact copies of the original nonbiologic drugs. US
FDA requires verification of similar pharmacokinetic and
pharmacodynamic profiles to the original nonbiologic drug17
and also requires that the ratio of generic drug to the reference
product range between 0.80 and 1.25; this verifies adequate
bioequivalence to the generic’s reference product.8
In comparison, bioequivalence studies are required to
demonstrate that there is no clinically significant difference
between biosimilars and the originator reference product in
terms of their bioavailability.8
Interchangeability is defined as a high level of biosimilarity when compared to the reference biologic.9 US FDA
considers a biosimilar as interchangeable if it is “expected to
produce the same clinical result as the reference product in
any given patient” and “if administered more than once to an
individual, the risk in terms of safety or diminished efficacy of
alternating or switching between use of the biological product
and the reference product is not greater than the risk of using
the reference product without such (a) switch”.9

Biosimilar development
The notion that biosimilars are “similar but not identical”
adds to the concern about the safety and efficacy of biosimilars as compared to biologics. Each product batch of
biosimilars is unique from the next in terms of structure,
namely due to inevitable posttranslational modifications,
referred to as the “microheterogeneity phenomenon”.10 This
is not a new phenomenon, as even biologics are subject to
microheterogeneity due to biochemical modifications and the
complex manufacturing process.18 An example of microheterogeneity in a biosimilar that has been accepted by the EMA
is an increased number of phosphorylations on mannose-type
structures in epoetin alfa.19 Support for this acceptance is the
fact that the different phosphorylated structures are actually
common forms of recombinant erythropoietin.19
Generic drugs do not experience microheterogeneity due
to the formulaic synthesis of their small chemical structures.
In contrast to generic drugs, which are chemically based
and have highly predictable developmental processing, biosimilars express an inevitable level of variability in protein
folding among preparations even though the primary protein
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sequences are identical.10 This is due to the unique, organic
nature of synthesizing biologics in living organisms. During the intracellular processing of the biosimilar, different
modifications (eg, phosphorylations, protein clippings, and
glycosylation) are implemented to allow the cell to protect
the new protein during transportation into different cellular
compartments (Figure 1). Thus, data requirements for the production and marketing of biosimilars are far more than those
for generic chemical drugs, which have predictable characteristics. For generic chemical drugs to be approved, demonstration of similar pharmacokinetic profiles ( bioequivalence) to
the original chemical drug must be established. This proof
is typically adequate to conclude therapeutic equivalence
between the generic and original chemical drugs. In contrast,
biosimilars require meticulous comparison with the reference biologic, which involves a variety of methods including
comparability exercises.
To overcome potential disparity from protein to protein
in finished biosimilar batches, a thorough comparability
review of structural and functional properties as well as
the removal of process-related impurities is required.8 This
“comparability exercise” allows regulators to extensively
assess the quality, safety, and efficacy of the “newer” version postmanufacturing before final approval is given.18
The analytical assays determine the degree of structural
similarity of biosimilars and their reference products with
in vitro analysis using protein sequencing, nuclear magnetic
resonance spectroscopy, and chromatography to name a few.
Because biologic manufacturers realize that their active
product undergoes various sequences of modifications from
batch to batch, they currently use these well-established
methods to determine the comparability of each batch.20
The next course of action to discover variations that may
not have been detected during the in vitro molecular testing
phase is preclinical testing. This phase focuses on comparing
pharmacokinetics and pharmacodynamics of the drug to the
reference product in animal model testing.20 Clinical testing
on healthy volunteers is the last step in determining noninferiority and similarity between the biosimilar and original
product. Phase II clinical trials are omitted because the
goal is to establish that there are “no clinically meaningful
differences” in the safety and efficacy of biosimilars when
compared to the original biologic.10,20
Synthesizing biosimilars under multiple manufacturers
with different quality systems presents obstacles, including
product drift, evolution, and divergence.
Drift has been defined in a Product Quality Research
Institute–US FDA workshop as being “an unintended,
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Cloning and protein expression
Transfer into host cell
expression
screening/selection

Cloning into DNA vector
Source
DNA

Target DNA
Possibly same
gene sequence

Probably different
vector

Different cell expression
system

Protein production, purification, and validation
Cell
expansion

Cell production in Recovery through
bioreactors
filtration or
centrifugation

Purification through
chromatography

Characterization and
stability

Purified
bulk drug

Different cell line,
growth media,
and method
of expansion

Different cell line,
growth media,
and bioreactor
conditions

Different
operating
conditions

Different binding and
elusion conditions

Different methods,
reagents, and
reference standards

Figure 1 Variation in manufacturing techniques of biopharmaceuticals.
Note: Reproduced from Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19(3):411–419,31 by permission of Oxford University Press.

unexplained, or unexpected trend of measured process
parameter(s) and/or resulting product attribute(s) away from
its intended target value in a time-ordered analysis over the
lifetime of a process or product”.21 This deviation from the
intended biologic product may be a systematic trend or a
sudden shift in quality. Product drift may be managed with
vigorous quality system monitoring and close evaluation of
process parameters.21 Occasionally, biological drugs may drift
outside the boundaries of acceptable criteria of similarity due
to manufacturing changes, which is a phenomenon described
as product evolution.21
Product drift and evolution, over time, may contribute
to clinically significant differences between biosimilars and
their reference products. This cumulative effect is termed
divergence.21 In cases where the biosimilar and reference
product are produced by different manufacturers, the two
biologics that are initially similar may not remain comparable
over time. This loss in similarity may result from unrevised
drift by a manufacturer or the evolution of one or both of the
agents.21 The clinically meaningful differences of interest
include the potency, safety, and immunogenicity profiles. For
example, the biosimilar or reference product’s divergence in
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immunogenicity could affect its safety profile and efficacy
of a patient’s therapy.21

Regulatory process
Because biosimilars and generic drugs belong to different
drug categories, each is under its own unique regulation.
Biosimilars and generic drugs have separate data requirements for licensing in the US. For example, while generic
drugs must prove that they are copies of their reference
drug, biosimilars must undergo extensive comparison with
the reference biologic to confirm close similarity in regard
to biological features.10 Generic drugs are monitored by the
Federal Food, Drug, and Cosmetic Act, whereas biosimilars
are regulated by US FDA under the Public Health Service
Act.11 Through an amendment of the Public Health Service
Act by the Biologics Price Competition and Innovation Act
(BPCIA) of 2009, an approval pathway for biosimilars was
established.22
The Affordable Care Act of 2010 included the BPCIA,
which aims to provide a solution for protecting against biologic monopoly by allowing competition to enter the market
while still encouraging the innovation of new drugs.5 The
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BPCIA provides a pathway for competition for potential
biosimilar entrance into the market once patent protection
for biologics has expired.5 Patent protection for originator
biologics expires 20 years from the file date of the patent
application. Once US FDA issues market approval, the
BPCIA grants marketing exclusivity for 12 years and a 4-year
data exclusivity for the originator biologic agent. A 6-month
exclusivity extension can be given to pediatric applications.5
The BPCIA created an abbreviated application pathway
(the 351k path) for biosimilars, which minimizes the testing
required in animals and humans, referred to as the abbreviated
biologics license application (aBLA).5 The aBLA’s expedited
process of biosimilar approval, in comparison with that of
biologics, aims to encourage more applicants to reach the
market quicker in order to introduce competition, thereby
increasing the consumer benefit.5 In order to be approved
for the 351k path, products must prove their similarity to
the reference in terms of using the same indication, dosing,
route of administration, mechanism of action, and potency.11
Although recent legislation has allowed the abbreviated processing of biosimilars, the caveat is that US FDA
requires numerous nonclinical studies proving the safety and
efficacy, a clinical trial, and an immunogenicity study.9 This
may offer less motivation for pharmaceutical companies to
invest in biosimilar production through the aBLA. Biologics
approved under the biologics license application benefit from
an exclusivity period, patent licensing, and a larger sample
size. In contrast, biosimilars processed under the aBLA have
no rights to exclusivity or patent privileges, which may make
investing in biosimilar production a more complex decision
for pharmaceutical companies.5
Both domestic and international efforts are underway for
promoting the utilization of biosimilars. The World Health
Organization composed a guideline for biosimilars in 2009
for the purposes of creating an international resource to
guide clinical trials, establish pharmacovigilance, and serve
as a reference for countries with less developed pharmacovigilance regulations.23 Since its publication, this universal
resource has influenced the construction of many nations’
own approval protocol for biosimilars.
As mentioned previously, the EU leads the nations in
pursuing biosimilar utilization. Motivated by the expiration
of biologic patents, including epoetin alfa and somatropin,
the EMA created the first ever biosimilar regulatory guideline
in 2005. The guideline requires proof of biosimilar purity,
efficacy, and pharmacovigilance data as validated by clinical studies and extrapolation analysis.9 In 2006, the EMA
issued further guidance pertaining to matters concerning
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biosimilar approval, including quality issues of analytical
studies as well as clinical and nonclinical issues. The guidelines sought to ensure that proper reference biologics were
chosen for each biosimilar, methods and product indications
were clearly stated, biologic activity was sufficiently proven,
pharmacophysiologic mechanisms were clear and correct,
and postmarketing safety monitoring protocols were in place.
With current biosimilar regulatory guidelines in revision, the
EMA has also created class-specific biosimilar guidelines that
include categories, such as recombinant therapeutic proteins
and monoclonal antibodies.9
Although Europe and India have created guidelines to
manage biosimilars in 2006 and 2012, respectively, the US
is trailing behind having only recently issued the first draft
of biosimilar guidelines in 2014.20
US FDA defines biosimilars as being highly similar
to its US FDA-approved reference biologic product as far
as quality, safety, and potency.11 US FDA has issued draft
guidelines to provide a course of action for applicants to
demonstrate “biosimilarity”, requiring structural–functional
analysis, results of animal studies offering pharmacokinetic
and safety data, and extrapolations for indications as supported by evidence-based medicine. The guidelines also
request background information of the biosimilars, including
information on the manufacturing process, impurities, and
drug stability.11 Per guidelines, comparative analytical assay
studies are recommended to describe the protein structure,
posttranslational modifications, functional activity, and toxicity as compared to reference.9
Following analysis, pharmacophysiologic studies are
recommended to demonstrate mechanisms of action. Clinical
trials and postmarketing surveillance monitoring are recommended to assess the safety profile of the biosimilar.9 US FDA
also addressed the naming of biosimilars. They proposed the
use of the reference product’s core name (eg, trastuzumab)
with an assigned four-lowercase letter suffix attached with
a hyphen (eg, trastuzumab-abcd) to help medical providers
differentiate the reference drug from its biosimilar.24
State regulations of US vary in regard to pharmacist
substitution for biologics written by the prescribing physician. Whether automatic substitution of a biosimilar for a
biologic in written prescriptions is deemed by US FDA to be
interchangeable or not depends on each state’s laws as well
as judgment from the state pharmacy boards according to
the BPCIA of 2009.9 Automatic substitution laws are especially of importance for biologic drugs that are prescribed
to patients to be obtained from retail pharmacies for selfadministration (eg, supportive care biologics).9 This is in
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Table 2 Typical features of state legislation related to biologic medications and substitution of biosimilars according to the NCSL as
of 2015
NCSL: state laws and legislation related to biologic medications and substitution of biosimilars
Any biological product under consideration for substitution must first be approved as “interchangeable” for substitution by US FDA.
The prescriber (such as a physician, an oncologist, and a physician assistant) would be able to prevent substitution by stating “dispense as written” or
“brand medically necessary”.
The prescriber must be notified of any allowable substitution made at a pharmacy. (This would allow a physician to assess and compare the patient
experience).
The individual patient must be notified that a substitute or switch has been made. In some cases, state law would require patient consent before any
such switch is made.
The pharmacist and the physician must retain records of substituted biologic medications.
The pharmacist would not be liable in any way for the dispensing of an interchangeable biological product if it complied with the listed state law
provisions.
The state must maintain a public list of permissible interchangeable products.
Note: Data from Jelkmann.25
Abbreviations: NCSL, National Conference of State Legislatures; US FDA, US Food and Drug Administration.

contrast to biologics that must be dispensed in an inpatient
or outpatient setting (eg, chemotherapeutic biologics for
cancer), where the retail pharmacy substitution process is
generally not an issue.5
According to the National Conference of State
Legislatures, as of July 2015, 15 states have enacted
and signed statutes regarding biosimilar substitutions
for biologics, which include Delaware, Florida, Indiana,
Massachusetts, North Dakota, Oregon, Utah, Virginia,
Washington, Texas, Louisiana, Tennessee, North Carolina,
Georgia, and C
 olorado. Seven states have filed bills that
have either failed or were adjourned, and five states have
pending legislation. Puerto Rico, New Jersey, and Illinois
have passed legislation, but there is no state law. California’s
legislation was passed but vetoed in 2013. Typical features of
state legislation are listed in Table 2, many of which rely on
the interchangeability between biologics and biosimilars.25
Interchangeability presents a growing concern for clinicians, as they may not be asked for permission to have a biosimilar substituted for the prescribed biologic agent for their
patient with automatic substitution. Although generic drugs
are routinely interchanged for original therapeutic agents, the
risk of immunogenicity from the repeated substitutions is low
compared to biosimilars. The EMA allows the individual EU
states to decide on this matter.26 US FDA has not yet issued
regulatory information about how they plan to determine
interchangeability for substitutions. Of note, no biosimilars
are currently approved as interchangeable by US FDA.

Safety and efficacy
Repeated switching between biosimilars and their reference
products carries a theoretical risk of patients developing immunogenicity; however, this risk is also present when switching
occurs between batches of reference products. Immunogenicity
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is the induction of an antibody response by a drug, a phenomenon unique among biopharmaceuticals.20 Immunogenicity
profiles of biologic drugs are of prime interest, as they have
the potential to compromise the safety and efficacy of the
drug.9 The factors contributing to the immunogenic profile of
a biologic include the product characteristics, the underlying
disease processes, and the patient’s unique factors. The disease
processes and patient factors have already been studied during
the development of the associated reference biologic, so the
main component of immunogenicity in biosimilars that should
be scrutinized is the product characteristics. The inevitable
microheterogeneity in biosimilar structures, such as unique
posttranslational modifications and protein aggregation, could
have a significant impact on immunogenicity.9
A well-known example of immunogenicity was the development of neutralizing antibody-mediated pure red cell aplasia
resulting from the substitution of polysorbate 80 and glycine for
albumin as a stabilizer in Eprex®. Eprex® was a recombinant
human erythropoietin formulation for patients with chronic
renal failure in Europe.27 Of note, it was approved as a biologic
not as a biosimilar. A second pure red cell aplasia incident
occurred with the administration of a subcutaneous epoetin biosimilar HX575® during a clinical trial in Europe. The trial was
subsequently terminated after two patients formed neutralizing
antibodies while on the medication. Researchers speculated
that resultant immunogenicity from HX575® could have been
caused by a structural modification during manufacturing.27
Due to the confidentiality of pharmaceutical company
trade secrets, such as the details of manufacturing processes
for licensed biologics, biosimilar developers must establish
their own unique manufacturing process after careful and
extensive research of the original biologic.28 Also, having
previous knowledge and expertise about the process of
developing biologics and the ability to use “reverse engineer-
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ing” increase the likelihood of biosimilarity.29 However, the
inevitable posttranslational modifications that occur during
the intracellular processing of the biosimilar causing microheterogeneity from its reference product create a concern
about their potential for immunogenicity.
Postmarketing surveillance of the safety of biosimilars is
needed for complete reassurance, in addition to premarketing
safety analysis and animal studies, in order to ensure ongoing comprehensive monitoring.30 The standard protocol for
a new drug application requires the composition of a risk
management plan, which discusses potential safety concerns
with the drug and submission of the protocol to US FDA
for the postmarketing surveillance process. In the case of
a biosimilar applicant with a known rare presentation of an
immune response that is unlikely to be detected preceding
licensing, the biosimilar may undergo expedited approval
and require an additional postmarketing study to discover
potential incidences.30
US FDA supports the extrapolation of biologic indications
to cover their respective biosimilars even if formal i nvestigation
of the biosimilar for those additional indications has not been
performed.9 A biosimilar used to treat a disease, such as rheumatoid arthritis, may also be approved for another disease, such
as psoriasis, without going through a clinical trial since the
corresponding reference biologic would have the same indications. For US FDA approval of extrapolations, it is important
that the biosimilar applicant clinically supports that it shares
the same distribution, mechanism of action, pharmacokinetics, pharmacodynamics, effectiveness, and potential toxicity.9

Conclusion
Biosimilars are at the forefront of medicine changing the
landscape and offering an option for helping to alleviate health
care’s ever rising costs. By introducing competition, there is
potential for reduction in health care costs of associated biopharmaceuticals and the creation of a more affordable biologic
market. Newer biosimilars, which are thought of as “biobetters” or “biosuperiors”, are also in development to mimic and
improve upon the biologic reference’s administration, mechanism of action, pharmacokinetics, and pharmacodynamics.11
With the influx of new biologic alternatives, there is a
critical need for the development of analytical tools and
assays with specific end points to better demonstrate similarity of biosimilars in applying for US FDA approval.11 Analytical studies must be enhanced to adequately predict the
immunogenicity potential, a required reported component
for US FDA approval.9
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To date, biosimilar use has been very successful in
Europe and other countries, thus serving as a model for the
US along with the World Health Organization international
guidelines.9 In order to take advantage of the benefits of
biosimilars, there is a need for open communication within
the medical community to facilitate awareness and knowledge about the safety and efficacy of biosimilars and the
appropriate use in patients.
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